Cargando…
Three-Year Outcomes Following Permissive Cardiotoxicity in Patients on Trastuzumab
INTRODUCTION: Cardiotoxicity, manifest by reduced left ventricular ejection fraction (LVEF), is the most common reason for the premature discontinuation of trastuzumab. While permissive cardiotoxicity (where mild cardiotoxicity is accepted to enable ongoing trastuzumab) has been shown feasible, the...
Autores principales: | Zhou, Shijie, Cirne, Filipe, Chow, Justin, Zereshkian, Arman, Bordeleau, Louise, Dhesy-Thind, Sukhbinder, Ellis, Peter M, Mukherjee, Som D, Aghel, Nazanin, Leong, Darryl P |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10485282/ https://www.ncbi.nlm.nih.gov/pubmed/37094996 http://dx.doi.org/10.1093/oncolo/oyad086 |
Ejemplares similares
-
Pertuzumab Cardiotoxicity in Patients With HER2-Positive Cancer: A Systematic Review and Meta-analysis
por: Alhussein, Muhammad Mustafa, et al.
Publicado: (2021) -
Safety of Continuing Trastuzumab Despite Mild Cardiotoxicity: A Phase I Trial
por: Leong, Darryl P., et al.
Publicado: (2019) -
Detection of Macrotroponin in Patients Receiving Treatment for Breast Cancer
por: Kavsak, Peter A., et al.
Publicado: (2023) -
Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials
por: Farooqi, Mohammed A. M., et al.
Publicado: (2018) -
Signal Detection of Adverse Events Associated with Trastuzumab in a Cohort of Elderly Patients with Breast Cancer
por: Polychronopoulou, Efstathia, et al.
Publicado: (2022)